Andrew Kirkendall is a personal injury attorney practicing law in Dallas, Texas.
He began his legal career at the litigation boutique McKool Smith in Dallas, where he represented a Fortune 500 company in a contract dispute, represented a CEO in an employment dispute, and advised companies regarding trademark issues.
While he found such work both interesting and challenging, in 2007 Andrew decided to change the trajectory of his legal career. Instead of representing large corporations, he decided that his talents would better serve states and individuals injured by the actions of pharmaceutical companies, He left McKool Smith to join Bailey Perrin Bailey in Houston, where he gained extensive experience in pharmaceutical litigation. He represented several state attorneys general against the manufacturers of atypical antipsychotic drugs, including Eli Lilly, Astra Zeneca, and Johnson & Johnson. In addition, Andrew represented individuals who were injured by the atypical antipsychotic Seroquel. He also represented individuals against the wealth management firm Morgan Keegan in a securities fraud arbitration.
In 2011, Andrew decided to bring his experience and knowledge to the founding of his own firm, and shortly thereafter joined together with Alexander Dwyer to create Kirkendall Dwyer LLP. Andrew represents individuals injured by pharmaceuticals and medical devices, and has successfully resolved cases for users of drugs such as Yaz and Avandia. In addition, as a Dallas personal injury lawyer, he represents individuals harmed by the negligence of others, such as in motor vehicle and maritime accidents.
Andrew graduated from the University of Texas in 2000 with a degree in Government. In 2005, he received his Juris Doctor, cum laude, from The Dedman School of Law and his Masters in Business Administration from the Cox School of Business, both at Southern Methodist University. While at SMU, he served as Managing Editor of the SMU Law Review. He received the distinguished honor of having his article Filling in the GAAP: Will the Sarbanes-Oxley Act Protect Investors from Corporate Malfeasance and Restore Confidence in the Securities Market published in the SMU Law Review.
Andrew is currently an active member of the Texas Trial Lawyers Association, the American Association for Justice, and is on the Board of Directors of the Dallas Trial Lawyers Association.
From the very first phone call, you will find that Andrew will treat your case with the compassion and attention it deserves. If you are looking for Dallas personal injury attorneys, contact Andrew by filling out a form today.